课题基金 / 基金详情

铈NPs夹心离子共敏化介孔硅纳米颗粒通过抑制ZIP8-Zn-MTF1轴调控类风湿关节炎巨噬细胞极化的机制研究

批准号:
82102531
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
张克石
依托单位:
学科分类:
运动系统免疫相关疾病
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
张克石

项目摘要

结项摘要

相似基金

相关文献

中文摘要
类风湿关节炎(RA)最重要的发病机制是滑膜炎症性病变,但其具体机制尚不明确。近年已发现滑膜巨噬细胞极化、锌稳态失衡在RA发病机制中均起到重要作用。本研究计划构建一种新型的CeO2介孔硅纳米颗粒(CeO2@MSN),并将II型胶原蛋白抗体修饰于其表面,承载于水凝胶微球,将其注射到胶原诱导关节炎动物模型的关节腔中观察其治疗效果,并检测在锌代谢稳态中起重要作用的ZIP8-Zn-MTF1轴在该介孔硅颗粒租用下发生的变化及其相应的分子机制,观察锌代谢在此过程中发生的变化并总结其规律。同时,在体外细胞模型研究中,通过对ZIP8-Zn-MTF1轴的调控,观察巨噬细胞极化所发生的改变及其分子细胞生物学过程,从而研究RA滑膜巨噬细胞极化改变的规律和具体机制,并明确CeO2@MSN治疗RA的潜在原理,进一步探究RA滑膜炎性病变的机制,为探索RA的发病机理和潜在的治疗靶点提供新的理论基础。
英文摘要
Inflammatory lesions of the synovium is the most important pathogenesis of rheumatoid arthritis (RA), of which the specific mechanism is still unclear. In recent years, it has been found that the polarization of synovium macrophages and the homeostasis imbalance of zinc metabolism play important roles in the pathogenesis of RA. The present project aims to build a novel CeO2 meso-porous silicon nanoparticles (CeO2@MSN) and modify type II collagen antibodies on their surfaces, carrying them in hydrogel microspheres, and injecting them into the joint cavity of collagen-induced arthritis animal models. The therapeutic effect, as well as the changes and corresponding molecular mechanisms of ZIP8-Zn-MTF1 axis which played an important role in zinc metabolic stability, would be observed, with the changes of zinc metabolism in this process and the corresponding regularity. Meanwhile, in the study of in vitro cell models, with changes in the regulation of ZIP8-Zn-MTF1 axis, the macrophage polarization and their molecular cell biologic process will be observed, so as to study the specific mechanism of RA synovium macrophage polarization, in order to clarify the potential principle of CeO2@MSN in the therapy of RA, to further explore the mechanism of RA synovium inflammatory lesions, and to provid a new theoretical basis for the pathogenesis and potential therapeutic targets of RA.
本课题研发制作并表征了一个由纳米级载药体构成的治疗单元和一个由微米级缓释微球所构建的缓释单元,然后将这两者共价结合,制备成用于关节腔内注射的长效抗炎缓释载药系统,为未来关节炎的新型非手术治疗方式的开发提供实验基础。纳米载药治疗单元是基于温差液相沉淀-老化法、溶胶-凝胶模板套封技术、硅烷氨基偶联方法来制作的。缓释单元是通过光固化微流控平台技术和碳二亚胺-羧基失水酰胺化的材料修饰工艺来制作的。这两者通过亲和素-生物素系统进行共价结合,形成新的显微结构,最终制备成用于关节腔内注射的长效抗炎缓释载药系统。相应材料学特性的表征检测和体外、体内有效性验证试验证实该系统理化性质符合预期,在体外与动物模型体内均表现了良好的安全性与缓释效果,并有潜在的抗炎性反应、抑制新生血管生成效应,这一效应可能与其影响了巨噬细胞极化有关。
国内基金
海外基金